Intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4
Cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on days -3 and -2

Intravenous busulfan 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4.
Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2

Leukemia

Myelodysplastic Syndrome

BuCy vs BuFlu

Asan Medical Center

Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen

Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome

Je-Hwan Lee

Cooperative Study Group A for Hematology

Toxoplasmic Encephalitis

AIDS

TMX-SMX (Bactrim(R))

Pyrimethamine plus Sulfadiazine plus leucoverin

Chiang Mai University hospital (2003-2004)

Treatment of Cerebral Toxoplasmosis in HIV/AIDS

Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients: A Randomized Controlled Trial.

Rajavithi Hospital

Chiang Mai University

FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.

FOLFIRI Plus Bevacizumab

Sex: Female, Male

Region of Enrollment

PFS is defined as the duration of time from start of treatment to time of disease progression using Kaplan-Meier median PFS time.

Median Progression-free Survival (PFS)

Overall Study

Scott Kopetz, MD Associate Professor

Colorectal Cancer

400 mg/m^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.
2.4 g/m^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m^2 injection.

5-Fluorouracil

5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.
5 mg/kg by vein on Day 1 of 14 day cycle.

Bevacizumab

400 mg/m^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.

Leucovorin

180 mg/m^2 by vein over 90 minutes on Day 1 of 14 day cycle.

Irinotecan

Lyndon Baines Johnson General Hospital

UT MD Anderson Cancer Center

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

Phase II Study of Irinotecan, Leucovorin, 5-Fluorouracil (FOLFIRI) Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer

folinic acid/karščiavimas

Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen

Treatment of Cerebral Toxoplasmosis in HIV/AIDS

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu